The likelihood of approval (LoA) of Chengdu Kanghong Pharmaceuticals’ (SHE:002773) Phase III conbercept in neovascular age-related macular degeneration (AMD) dropped 7 points as of 12 April, according to GlobalData’s LoA data. The drop came as the company said on 9 April the Phase III PANDA-1 (NCT03577899) trial will stop.
The statement noted that global health emergencies and changes in external environments had caused great difficulties for the clinical research as large numbers of the 1,140 patients have stopped treatment, missed follow-ups, and exceeded testing windows. The number of cases tested for the dosing regimen is now less than 40% of the enrolled cases, it said. The trial has been unable to obtain results with registrational value, it added.
The vascular endothelial growth factor (VEGF) and placental growth factor (PIGF) inhibitor had an LoA of 37% for AMD. Based on GlobalData’s analysis using a combination of machine learning and a proprietary algorithm, the LoA has dropped to 30%. Conbercept prevents VEGF and its endothelial cell surface receptor binding, blocking its biological activity and inhibiting endothelial cell proliferation and angiogenesis.
Sean Rai-Roche is a Healthcare Reporter for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.